CSI Market
Sign In | Register

Nascent Biotech Inc (NBIO) Annual Cash Flow Statement

Annual · GAAP · USD millions
Access NBIO quarterly Cash Flow →
Changes in quarterly cash flow trends offer perspective on how Nascent Biotech Inc funds operations, investments, and shareholder returns.
View historic periods: Download as CSV:
Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.
Annual Report, GAAP in USD millions
ITEM 		(Mar 31 2024)
12 Months 		(Mar 31 2023) (Mar 31 2022) (Mar 31 2021) (Mar 31 2020)
Operating Activities
Income-2.09
Depreciation & amortization0.00
Amortization of Other Assets0.38
Increase (Decrease) in Deferred Revenue0.00
Restructuring & Impairment Charges0.00
Provision For Loan Losses Expensed0.00
Inventories Decrease /-Increase0.00
Research and Development in Process0.00
Gain (Loss) on Disposition of Assets0.00
Share-based Compensation0.11
Income (Loss) from Equity Method Investments0.00
Gains (Losses) on Extinguishment of Debt0.00
Change In Fair Value Of Derivative Liability-
Litigation Settlement Amount-
Stock Based Compensation Related Parties-
Dividends Sharebased Compensation Stock-
Derivative Gain Loss On Derivative Net-
Debt Conversion Original Debt Amount-
Gain Loss On Foreign Currency Fair Value Hedge Derivatives-
Loss On Notes-0.05
Share Based Compensation Related Parties0.77
Gain Loss In Fair Value Of Derivative Liability-0.47
Loss On Convertible Notes-
Increase Decrease In Due To Related Party-
Income taxes0.00
Unrealized Gain (Loss) on Derivatives0.00
Increase (Decrease) in Accounts Receivable0.00
Increase (Decrease) in Accounts Payable and Accrued Liabilities0.26
Increase (Decrease) in Accrued Liabilities0.00
Increase (Decrease) in Customer Advances0.00
Increase (Decrease) in Prepaid Expense-0.10
Other Working Capital0.00
Other Noncash Income (Expense)0.00
Other net0.00
Payments for (Proceeds from) Other Operating Activities0.00
Discontinued operations0.00
Net Cash flow from Operating Activities-1.19
Investing Activities
Capital Expenditures0.00
Sale of Capital Items0.00
Short-term Investments Proceeds0.00
Short-term Investments Acq.0.00
Real Estate Investments0.00
Restricted Cash and Investments Increase (Decrease)0.00
Payments for (Proceeds from) Loans0.00
Payments for (Proceeds from) Deposits0.00
Payments for (Proceeds from) Other Investments0.00
Payments for (Proceeds from) Federal Reserve and FHLB0.00
Acquisition Net of Cash Acquired0.00
Interest in Subsidiaries and Affiliates0.00
Sale of businesses0.00
Accounts payable0.00
Receivables0.00
Payments for (Proceeds from) Other Investing Activities0.00
Other Net0.00
Discontinued operations0.00
Net Cash Flow from Investing Activities0.00
Financing Activities
Short-term debt Net0.00
Other borrowing transactions0.00
Long-term debt - borrowings0.23
Long-term debt - repayments-0.40
Federal Home Loan Bank and Federal Funds0.00
Issuances / -repurchases of Comm. Stock1.56
Partnership and Parent Transactions0.00
Issuances / -repurchases of Pref. Stock0.00
Deposits, Annuities, Contract Holders Funds0.00
Other financing activities net0.00
Other net0.00
Debt Conversion Converted Instrument Amount-
Stock Issued During Period Shares Stock Options Exercised-
Repayment Of Convertible Notes-
Common Stock Issued For The Exercise Of Warrants-
Proceeds From Warrant Conversion-
Payments of Dividends, Preferred Stock and Preference Stock0.00
Dividends paid0.00
Net Cash Flow from Financing Activities1.39
Effect of exchange rate on cash flow0.00
Discontinued operations0.00
Free Cash Flow-1.19
Total Cash Flow0.20
4 historic quarters locked

Sign in to unlock the full Nascent Biotech Inc cash flow history.

Sign In Create Free Account

About Nascent Biotech Inc Annual Cash Flow Statement

What this statement shows

This page presents issuer-reported cash flow data, including operating, investing, financing, net, and free cash flow, as disclosed in SEC 10-K filings and normalized by CSIMarket.

Source & verification

  • Form: 10-K (Period: 20240331)
  • Filed with the SEC: July 1, 2024
  • Source: nbio_10k.htm

Last updated

  • Page updated:
  • Data lineage: SEC filings - XBRL extraction - normalization in the CSIMarket.com database.
  • Accession: 0001477932-24-004020

Figures are derived from filed reports and may be restated. Historical data is subject to revision.

Untitled Document 





                    


    



  Get the full CSIMarket dataset:
  Subscribe
  API
  License